Evidence map›Paper›PMID 38962038›Full record

ArticleInternational cancer conference journal2024

A patient who underwent conversion surgery after atezolizumab plus bevacizumab for hepatocellular carcinoma with portal vein thrombosis and perihepatic lymph node metastases achieved a pathological complete response.

Masayuki Okuno, Hideko Ohama, Ikuo Nakamura, Makoto Yoshida, Daisuke Shirai, Takahito Hirai, Hiroaki Fuji, Ami Kurimoto, Tomohiro Okamoto, Hideaki Sueoka and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International cancer conference journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Masayuki OkunoDepartment of Gastroenterological Surgery, Hyogo Medical University, Nishinomiya, Japan.ORCID 0000-0001-5708-6384
Hideko OhamaDepartment of Gastroenterology, Takarazuka City Hospital, Takarazuka, Japan.
Ikuo NakamuraDepartment of Gastroenterological Surgery, Hyogo Medical University, Nishinomiya, Japan.
Makoto YoshidaDepartment of Surgical Pathology, Hyogo Medical University, Nishinomiya, Japan.
Daisuke ShiraiDepartment of Gastroenterological Surgery, Hyogo Medical University, Nishinomiya, Japan.
Takahito HiraiDepartment of Gastroenterological Surgery, Hyogo Medical University, Nishinomiya, Japan.
Hiroaki FujiDepartment of Gastroenterological Surgery, Hyogo Medical University, Nishinomiya, Japan.
Ami KurimotoDepartment of Gastroenterological Surgery, Hyogo Medical University, Nishinomiya, Japan.
Tomohiro OkamotoDepartment of Gastroenterological Surgery, Hyogo Medical University, Nishinomiya, Japan.
Hideaki SueokaDepartment of Gastroenterological Surgery, Hyogo Medical University, Nishinomiya, Japan.
Kenjiro IidaDepartment of Gastroenterological Surgery, Hyogo Medical University, Nishinomiya, Japan.
Masaharu TadaDepartment of Gastroenterological Surgery, Hyogo Medical University, Nishinomiya, Japan.
Takako KiharaDepartment of Surgical Pathology, Hyogo Medical University, Nishinomiya, Japan.
Hironori TanakaDepartment of Gastroenterology, Takarazuka City Hospital, Takarazuka, Japan.
Seiko HironoDepartment of Gastroenterological Surgery, Hyogo Medical University, Nishinomiya, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here, we present a patient with hepatocellular carcinoma complicated by tumor thrombosis into the main portal trunk and perihepatic lymph node metastases who was treated with atezolizumab plus bevacizumab. Shrinkage of the main tumor, portal vein thrombosis, and lymph node metastases were achieved; therefore, hepatectomy with lymphadenectomy could be performed. Final pathology indicated a complete pathological response in the main tumor, portal vein thrombosis, and perihepatic lymph nodes. The patient is currently alive with no evidence of recurrence on radiological assessment at 3 months after surgery.

Indexed as

Advanced stageHepatectomyImmunotherapy

Identifiers

PMID38962038
PMCPMC11217228

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.